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Abstract 
Owing to the nature of acute illness and adverse effects derived from intensive chemotherapy, patients with hemato-
logical malignancies (HM) who are admitted to the Intensive Care Unit (ICU) often present with poor prognosis. How-
ever, with advances in life-sustaining therapies and close collaborations between hematologists and intensive care 
specialists, the prognosis for these patients has improved substantially. Many studies from different countries have 
examined the prognostic factors of these critically ill HM patients. However, there has not been an up-to-date review 
on this subject, and very few studies have focused on the prognosis of patients with HM admitted to the ICU in Asian 
countries. Herein, we aim to explore the current situation and prognostic factors in patients with HM admitted to ICU, 
mainly focusing on studies published in the last 10 years.
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Background
The triage and management of patients with hematologi-
cal malignancies (HM) in life-threatening situations pre-
sents a paradox for clinicians (Hill 2010). Historical research 
established more than 25 years ago found that HM patients 
admitted to the intensive care unit (ICU) have poor prog-
nosis due to their acute illness and adverse effects resulting 
from intensive chemotherapy (Lloyd-Thomas et al. 1988; Yau 
et al. 1991; Brunet et al. 1990). Undeniably, recent advances 
in life-sustaining therapies and close collaborations between 
hematologists and intensive care specialists have resulted in 
a paradigm shift and in the improvement of the prognosis 
of patients with HM admitted to the ICU (Hampshire et al. 
2009; Azoulay et al. 2013; Bird et al. 2012; Hill et al. 2012). 
In Western countries, the ICU mortality rate of patients 
with HM has abated from 65 to 80% in the 1980s (Lloyd-
Thomas et  al. 1988; Yau et  al. 1991; Schuster and Marion 
1983) to 34–56% today (Hampshire et  al. 2009; Bird et  al. 
2012; Geerse et al. 2011). A large prospective trial performed 
by Azoulay et al. (2013) noted that the hospital, day-90, and 
1-year survival rates for patients with HM admitted to ICU 
were 60.7, 52.5, and 43.3%, respectively. Additionally, while 
many studies from different countries have examined the 
prognostic factors of these critically ill HM patients, the rela-
tive significance of many factors remains controversial, as 
many of them have not been confirmed in multicenter pro-
spective studies (Hampshire et  al. 2009; Lamia et  al. 2006; 
Gordon et al. 2005; Evison et al. 2001; Benoit et al. 2003; Liu 
et  al. 2015). To the best of our knowledge, there has been 
no up-to-date review on this subject since 2010 (Hill 2010). 
Accordingly, we might ask, has the value of some classical 
prognostic factors changed? Furthermore, most of the earlier 
studies were mainly focused on Western countries, while an 
increasing number of Asian countries have published studies 
that have shown different results regarding this subgroup of 
patients. For example, in some retrospective study in China 
(Evison et al. 2001; Benoit et al. 2003; Liu et al. 2015), HM 
patients had higher mortality rate and less access to the 
ICU, as compared to reports published by Western coun-
tries (Azoulay et al. 2013; Bird et al. 2012; Merz et al. 2008). 
Considering this point of view, whether Asian countries will 
compare with each other remains elusive, and it is unclear 
what factors might contribute to the different prognosis 
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observed in these countries. We aim to explore these ques-
tions in this review article, with a particular focus on studies 
published in the last 10 years.
Clinical factors
Factors predictive of prognosis for HM patients admitted 
to the ICU
Use of mechanical ventilation
Most studies have shown that acute respiratory failure is one 
of the primary reasons for ICU admission for critically ill HM 
patients (Bird et al. 2012; Geerse et al. 2011; Merz et al. 2008). 
Generally, there are three ways to improve respiratory fail-
ure: supplemental oxygen (e.g., nasal cannula or face mask), 
invasive mechanical ventilation (IMV, e.g., via an endotra-
cheal tube or tracheostomy), or noninvasive mechanical 
ventilation (NIMV, e.g., bilevel or continuous positive airway 
pressure). A large retrospective study in 2000 was the first 
to identify IMV as strong prognostic factor in critically ill 
patients with HM (Staudinger et al. 2000), and this was later 
proved to be the case in nearly all studies (Lloyd-Thomas 
et al. 1988; Geerse et al. 2011; Lamia et al. 2006; Evison et al. 
2001; Turkoglu et al. 2011; Kroschinsky et al. 2002; Owczuk 
et al. 2005; Rabbat et  al. 2005; Namendys-Silva et  al. 2013; 
Yeo et al. 2012). Generally, more than half of the critically ill 
HM patients need IMV to improve respiratory failure, and 
most of them eventually died in the hospital or ICU (Geerse 
et al. 2011; Liu 2015; Turkoglu et al. 2011). An explanation 
for the high mortality rate in this subgroup of patients may 
attribute to the co-occurrence of severe pulmonary dysfunc-
tion and nosocomial infections, such as ventilator-associated 
pneumonia (Kwak et al. 2010). The results of previous studies 
also showed that noninvasive mechanical ventilation could 
significantly reduce the rates of endotracheal intubation 
and serious complications, and thus plays a protective role, 
especially in immunosuppressed hosts (Hilbert et al. 2001a; 
Azoulay et al. 2001). Moreover, the improvement in NIMV 
significantly decreases the overall mortality rate of critically 
ill patients with HM (Liu et al. 2015; Belenguer-Muncharaz 
et al. 2013). In a multicenter, ten-year retrospective observa-
tional study, Belenguer-Muncharaz et  al. (2013) compared 
both IMV and noninvasive positive pressure ventilation 
(NPPV) in patients with HM admitted to the ICU. Their 
results revealed that the ICU mortality rate in the IMV group 
was three times as high as that in the NPPV group (100 vs. 
37%). Overall, NIMV has significantly decreased the risk of 
death by obviating the need for endotracheal MV in criti-
cally ill HM patients. On the other hand, the higher mortal-
ity after NIMV failure is in line with studies of patients with 
HMs (Molina et al. 2012; Gristina et al. 2011; Azoulay et al. 
2014), which calls for a more pragmatic approach towards 
the use of NIMV (Soares et al. 2010a). According to a pre-
vious study, first-line NIMV might be deleterious in patients 
in which the ARDS criteria has been met (Adda et al. 2008). 
The timely and earlier utilization of NIMV has been recom-
mended, as it can reduce the likelihood of intubation (Hilbert 
et al. 2001b), ventilator-associated lung injury (Azoulay et al. 
2001), and pneumonia or sepsis (Rabbat et al. 2005). In addi-
tion, the trials using high-flow nasal oxygen therapy (Mokart 
et al. 2015a) and extracorporeal gas exchange (Mokart et al. 
2015b) have shown that these modalities could be promis-
ing alternative approaches to mechanical ventilation in HM 
patients who also have severe acute respiratory failure.
The utilization of IMV is one of the most powerful pre-
dictors for predicting the outcome for patients with HM 
admitted to the ICU. The timely and appropriate use of 
NIMV can prevent the deterioration of respiratory fail-
ure, thus avoiding the need for patient intubation.
Organ failure
Organ failure is a powerful prognostic factor in non-can-
cer patients admitted to the ICU (Namendys-Silva et  al. 
2015; Leone et  al. 2015). Similarly, critically ill patients 
with HM admitted to ICU often suffer from multi-organ 
failure, which also plays an important role in their prog-
nosis (Hampshire et  al. 2009; Bird et  al. 2012; Gordon 
et al. 2005; Azoulay et al. 1999; Afessa et al. 1992). In an 
earlier study, only 1 of the 12 HM patients admitted to the 
ICU with multi-organ failure survived to discharge, and 
the authors proposed that HM patients with inadequate 
function in two or more organs are unable to benefit from 
intensive care (Brunet et  al. 1990). A more recent pro-
spective, multicenter cohort study confirmed that poor 
outcome was significantly associated with organ failure 
(Azoulay et al. 2013). Moreover, the number of dysfunc-
tional organs appears to have even more powerful predic-
tive value (Hampshire et al. 2009; Bird et al. 2012; Evison 
et  al. 2001; Namendys-Silva et  al. 2013). In another ret-
rospective study performed in Switzerland, the mortal-
ity rates of HM patients by day 60 after ICU admission 
were 16, 36, 64, and 83% for zero, one, two, or three failing 
organs, respectively (P < 0.0002) (Evison et al. 2001).
These data suggest that the early recognition and manage-
ment of organ failure can lead to more prompt ICU admis-
sion and therefore, better survival for patients with HM.
Scoring systems for overall wellness
Scoring systems have been proven to be of important 
value for estimating the risk of death and for evaluating 
the severity of the acute organ failure, especially in patients 
with HM, but were of less useful for predicting individual 
prognosis (Schellongowski et  al. 2004). There is consen-
sus that severity-of-illness scoring systems perform equal 
or even better than some other prognostic factors, such 
as underlying malignancies or disease status. Geerse et al. 
(2011) showed that the ICU mortality of critically ill HM 
patients was related to multiple organ failure and the need 
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for mechanical ventilation or inotropic/vasopressor ther-
apy. Therefore, the scoring systems should be considered 
as useful measures of the patient’s severity of acute illness.
Commonly used scoring systems include the fol-
lowing: Acute Physiology and Chronic Health 
Evaluation (APACHE and APACHE II), Sequen-
tial  Organ  Failure  Assessment (SOFA), and Simpli-
fied Acute Physiology Score (SAPS) (Schellongowski 
et  al. 2004; Sawicka et  al. 2014). Among these, SOFA is 
deemed to be the most frequently used system in HM 
patients admitted to the ICU (Geerse et al. 2011; Lamia 
et al. 2006; Merz et al. 2008). SOFA was initially devised 
in 1994 to assess the prognosis of patients with sepsis and 
septic shock (Vincent et al. 1996), and it has been widely 
used in ICU patients in recent years. Various forms of 
SOFA scores, which are taken at different points during 
the admission or ICU stay, have been used (Cornet et al. 
2005; Soares et al. 2010b). In one study, SOFA score ≥15 
was associated with 100% ICU mortality in HM patients 
(Cornet et al. 2005). Additionally, another large prospec-
tive multicenter study that included 50 HM patients (7% 
of all subjects) showed that high SOFA scores (OR 1.25; 
95% CI 1.17–1.34) were associated with severe organ fail-
ure and increased hospital mortality (Soares et al. 2010b).
Several other studies assessed the utility of monitoring 
the trend of SOFA scores over time to predict the mortal-
ity of HM patients admitted to ICU (Geerse et al. 2011; Liu 
et al. 2015). For example, Geerse et al. (2011) reported that 
patients with decreased SOFA scores through the course 
of ICU admission had significantly better prognosis than 
patients with unchanged or increasing SOFA scores. Our 
group replicated this result, and showed that the trend of 
the SOFA scores within the first 48  h of ICU admission 
had the most significant prognostic power (Liu et al. 2015).
The usefulness of APACHE II in HM patients is more 
controversial among the research literature. Some results 
have found its value for predicting mortality (Hampshire 
et  al. 2009; Owczuk et  al. 2005; Rabbat et  al. 2005; Yeo 
et  al. 2012; Parakh et  al. 2014), while others have not 
(Lloyd-Thomas et al. 1988; Hampshire et al. 2009; Afessa 
et al. 1992; Sawicka et al. 2014). Our previous study con-
firmed the important value of APACHE II, suggesting 
that this score system may aid in evaluating HM patients 
before and after ICU transfer in China (Liu et al. 2015).
The SAPS II scoring system was developed to gauge the 
risk of hospital mortality for ICU patients (Minne et  al. 
2012; Vosylius et al. 2004). Sawicka et al. (2014) evaluated 
different scoring systems, including APACHE II, SAPS II 
and SOFA. Their statistical analysis showed SAPS II score 
was the only independent risk factor of patient death in 
multivariate analysis (Sawicka et al. 2014).
Although all scoring systems provide an estimate of the 
severity of organ failure and acute illness in HM patients, 
none yields adequately comprehensive and reliable infor-
mation to be used alone. In addition, the scoring systems 
have only been used in retrospective or cohort studies 
with relatively small numbers of HM patients and were 
conducted at single academic institutions. Their use-
fulness needs to be yet confirmed in large prospective 
studies.
Hematopoietic stem cell transplantation (HSCT)
For selected patients with HM, stem cell  transplant  can 
provide long-lasting remission. After allogeneic HSCT, 
some patients inevitably require intensive care. However, 
the treatment and health care of general HM patients 
deviates significantly from HSCT patients, due to high 
doses of chemotherapy, severe immunosuppression, and 
isolation. The ICU mortality for HSCT patients is gener-
ally high, at 33–65% (Soubani et al. 2004; Bruennler et al. 
2007; Afessa et al. 2003; Pene et al. 2006). In recent years, 
the development of targeted therapy, careful patient 
selection, and more attentive post-transplant nursing, 
has substantially improved the outcome of these patients 
(Bird et al. 2012). A large retrospective cohort study per-
formed by Huynh et al. (2009) showed that the outcome 
of HSCT patients who required ICU-level care was not as 
poor as previously described, and the authors observed 
an improvement in the survival of HSCT patients who 
required mechanical ventilation. However, the outcome 
still remains poor for HSCT recipients who develop 
severe graft versus host disease (GVHD) or other severe 
complications (Schellongowski et  al. 2004; Sawicka 
et al. 2014). One study noted high mortality rates of up 
to 100% in ICU patients who developed multiple organ 
failures after bone marrow transplantation. However, the 
size of the subgroup in this study was too small for this 
observation to reach significance (Afessa et al. 1992). In a 
large study of 398 patients of HM admitted to ICU after 
HSCT, the morality rate was observed to be 100% if the 
patients developed acute lung injury, received more than 
4 h of pressors, or had sustained hepatic and renal fail-
ure (Rubenfeld and Crawford 1996). On the other hand, 
HSCT patients who do not have uncontrolled GVHD and 
remain on functional mechanical ventilation have been 
shown to have more optimistic survival rates (Pene et al. 
2006; Gooley et al. 2010; Price et al. 1998). Thus, HSCT 
recipients without severe organ failure or GVHD would 
likely benefit from intensive care. Knowledge deficits 
among ICU physicians on the caring of HSCT recipients 
may negatively affect the outcome as well. Accordingly, 
timely communication and close collaboration between 
hematologists and intensivists could improve patient 
care. In addition, future studies should compare the 
prognosis of patients who had undergone different types 
of HSCT.
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Controversial prognostic factors
Type and disease status of HM
HM is a broad category of diagnoses, which include both 
acute and chronic leukemias, various types of lymphomas, 
and dysfunctional hematopoiesis such as aplastic anemia. 
The disease statuses include newly diagnosed, remission, 
and relapsed or progression. Some previous studies have 
noted that both the type and status of disease were inde-
pendent prognostic factors for survival. For instance, the 
ICU mortality rate was lower for HM patients who were 
in remission status than those with progressive disease 
(Azoulay et  al. 2013; Aygencel et  al. 2014). Moreover, 
ICU mortality was significantly higher in patients diag-
nosed with acute leukemia (Yeo et al. 2012; Groeger et al. 
1999). For example, in one study, the ICU mortality rate of 
patients diagnosed with acute lymphatic leukemia (ALL) 
was as high as 100%, although the sample size was too 
small to make a scientific conclusion (Geerse et al. 2011).
With improvements in supportive care and unbiased 
patient selection, an increasing number of publications 
have revealed that the nature of HM does not influence 
patient prognosis (Lamia et  al. 2006; Benoit et  al. 2003; 
Merz et al. 2008; Bruennler et al. 2007). Some studies have 
demonstrated that patients with de novo acute myeloid 
leukemia or diffuse large B cell lymphoma show good long 
term prognosis if they survive the acute disease leading 
to ICU admission (Schellongowski et al. 2011; Wohlfarth 
et al. 2016). In a retrospective study, the rate of ICU dis-
charge was 48.8% in remission patients and 38.2% in 
active/progressive patients, which was not statistically sig-
nificant (Benoit et al. 2003). A separate study showed that 
underlying malignancies determined long-term survival, 
but did not predict ICU or hospital mortality (Massion 
et  al. 2002). Thus, whether the nature of the disease can 
significantly affect the prognosis of HM patients admit-
ted to the ICU remains debatable. In clinical practice, type 
and status of HM should not preclude ICU admission in 
patients who may otherwise benefit from intensive care.
Infection
Infection is a common reason for ICU admission, espe-
cially for critically ill patients (Schuster and Marion 1983; 
Schellongowski et  al. 2004). HM patients are more vul-
nerable to infection than other patients because of the 
nature of immunosuppression, medications, particularly 
steroids, chemotherapy, and stem cell transplant (Hol-
lis 1996). It was previously observed that the incidence 
of Gram-negative sepsis increased annually in patients 
with HM (Soubani et  al. 2004). The study performed by 
Hampshire et al. showed that the ICU mortality rate for 
HM patients suffering from severe infection reached 
66.6%, and infection was independently associated with 
high hospital mortality. The ICU mortality rate was even 
higher in HM patients with invasive fungal infection (Bird 
et  al. 2012; Sipsas and Kontoyiannis 2012), and reached 
79% in a longitudinal observation study (Bird et al. 2012).
However, existing research has not reached a defini-
tive conclusion on how infection affects survival. Some 
studies actually showed that HM patients had better out-
comes if the ICU admission was precipitated by bactere-
mia (Benoit et al. 2003, 2005; Depuydt et al. 2004, 2010). 
One explanation may be that bacteremia leads to prompt 
ICU admission and prevents the development of severe 
sepsis or septic shock. Variations in the definition of infec-
tion may also change its association with prognosis. Con-
firmed infection is usually defined as positive culture from 
a sterile site, but the diagnosis of some infections, such as 
pneumonia, often depends on clinical signs and radiologic 
judgments, which may not be accurate (Benoit et al. 2003; 
Reyes et al. 1999). Nevertheless, a broader ICU admission 
policy may be beneficial to patients with bacteremia.
Neutropenia
Neutropenia is generally defined as an absolute neutrophil 
count less than 1000/μL. The significance of neutropenia 
as a risk factor for HM patients at the time of admission to 
ICU or during the ICU stay remains controversial. Some 
publications have reported higher mortality in neutro-
penic patients, especially when mechanical ventilation 
is essential (Khwankeaw and Bhurayanontachai 2014). 
In a retrospective observational study, neutropenia was 
independently associated with poor outcomes (Benoit 
et  al. 2003). The higher mortality in this subgroup may 
be attributed to an increased susceptibility to nosocomial 
infections and severe sepsis (Benoit et al. 2003).
On the contrary, other researchers reported that neu-
tropenia was not independently associated with higher 
mortality in HM patients admitted to the ICU (Liu et al. 
2015). In our previous analysis, neutropenia at the time 
of admission was not a prognostic factor for ICU mortal-
ity (Liu et al. 2015). Interestingly, in another retrospective 
cohort study, mortality was not significantly higher, even 
when it persisted throughout the ICU stay or had been 
present for more than 21 days prior to admission (Geerse 
et  al. 2011). In these cases, the contribution of neutro-
penia may have been masked by the severe multi-organ 
failure these patients also suffered from (Blot et al. 1997).
Studies on HM patients from Asian countries
In the last decade, the ICU mortality rates for HM patients 
dropped to 26–56% in most of the western countries 
(Geerse et al. 2011; Evison et al. 2001; Benoit et al. 2003; 
Kroschinsky et  al. 2002; Rabbat et  al. 2005; McCaughey 
et al. 2013), although the mortality still remained higher 
for post HSCT patients (Townsend et  al. 2013). A study 
from Poland reported an ICU mortality of 75.7%, which 
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was much higher than the overall Western standard, and 
may be attributed to a comparably higher proportion of 
patients with mechanical ventilation (Sawicka et al. 2014). 
Presently, we could not find any studies published from 
African countries. Of most importance, studies published 
from Asian countries (China, Korean, India and so on) 
have revealed that the ICU mortality rate in these coun-
tries is higher than that in most western countries, rang-
ing from 55.2 to 84.1% (Liu et al. 2015; Khwankeaw and 
Bhurayanontachai 2014; Metan et  al. 2013; Bahammam 
et al. 2005; Park et al. 2011; Bajwa et al. 2010). More sur-
prisingly, the highest hospital mortality was shown to be 
in Korea (84.1%), where the access to advanced medical 
technology is relatively unrestricted (Yeo et al. 2012).
How can we explain the comparably high mortality rate 
in Asian countries? First, patients with HM admitted to 
the ICU in Asian countries may severely suffer from more 
organ failure and acute illness. For instance, the Asian 
studies had higher proportions of patients who required 
IMV or vasopressors (64% required IMV in Turkey and 
64.5% required IMV and 67.8% required vasopressors in 
China). A greater number of patients also had acute leu-
kemia and other acute malignancies, which are associated 
with a high risk for treatment-related complications (Liu 
et  al. 2015; Yeo et  al. 2012). Second, due to insufficient 
intensive care resources and high population densities, the 
more stringent ICU admission policies in these countries 
may have resulted in delayed care (Murthy et  al. 2015). 
For instance, only 0.61% of patients with HM were trans-
ferred to the ICU in our previous study involving a three-
hospital academic center in China, which is much lower 
than what was reported in a study from Brazil (5.9%) (Liu 
et  al. 2015; Lecuyer et  al. 2007). Additionally, the occu-
pancy of ICU beds in Asian countries is far less than that 
of western countries (Liu et  al. 2015). Previous studies 
have also shown that ICU centers with high volumes of 
patients with HM had significantly decreased mortality 
(Zuber et  al. 2012; Lecuyer et  al. 2008). Many research-
ers have suggested that a more reasonable goal is the early 
identification of the subgroup of patients whose probabil-
ity of survival is very low despite advanced ICU support 
(Khwankeaw and Bhurayanontachai 2014).  Moreover, 
the relatively high ratio of mortality to incidence in Asian 
countries may reflect different cultural beliefs. Accord-
ing to a large scale statistical analysis, 19% of patients in 
China who would otherwise deteriorate in the ICU were 
likely to be discharged home near the end of life, while in 
Brazil, this ratio was as high as 75% (Broad et al. 2013).
Therefore, the high ICU mortality rate may be stem 
from a combination of the study population character-
istics, the distribution of medical resources, and cultural 
differences on the end of life care. Most of the current 
data has come from early or retrospective studies, and 
further prospective and large multi-centered studies 
should test these hypotheses in Asian regions.
ICU admission policy
Most countries have relevant criteria regarding ICU admis-
sion for critically ill patients, and this is usually based on 
the need for treatments for organ failure, the frequency of 
monitoring for vital signs and the need for intensive nurs-
ing care (Liu et al. 2015). In most cases, the decision to shift 
to the ICU depends on an agreement between the specialist 
physicians and family members, which introduces subjec-
tive and emotional factors (Hill 2010). Because of family or 
patient wishes, some patients with excellent prognosis may 
be excluded from intensive care and vice versa. The major-
ity of studies that we reviewed recommended broader ICU 
admission criteria for HM patients to allow more patients 
to benefit from the higher level of care (Hill 2010; Hamp-
shire et  al. 2009; Aygencel et  al. 2014; Malak et  al. 2014; 
Azoulay et al. 2011; Thiery et al. 2005). The milestone of the 
“ICU trial” study performed by Lecuyer et  al. (2007) rec-
ommended that we should provide an alternative to ICU 
refusal in patients with malignancies for which potentially 
life-supporting treatments are available for improving their 
survival rates. In another large, prospective, multicenter 
cohort study, less than 24 h between presentation and ICU 
admission was associated with better hospital survival 
(Azoulay et al. 2013). Similarly, one study also revealed that 
the time elapsed between hospital and ICU admission was 
positively correlated with ICU mortality (Hampshire et al. 
2009). Consequently, broader admission policies can facili-
tate the admission of patients from the emergency depart-
ments to the ICU and the stepping-up of floor patients, 
thereby preventing treatment delay for critically ill HM 
patients with a high chance of deterioration. The prompt 
ICU admission of HM patients with acute respiratory fail-
ure or bacteremia could decrease the risk of intubation 
and septic shock (Depuydt et al. 2010). Conversely, delayed 
admission and suboptimal treatment may lead to the poor 
outcome in the ICU. In a large single-center study of HM 
patients admitted to the ICU in London, the ICU, in-hos-
pital, and 6-month mortalities were 33.7, 45.7 and 59.3%, 
respectively. The authors attributed the lower ICU mortal-
ity to the early and prompt admission of patients at high 
risk for organ failure based on the senior hematologists’ 
evaluation and the expert cancer care in the ICU (Bird et al. 
2012). The insight from this study suggest that special-
ist ICUs dedicated to the care of cancer patients may help 
increase the access of HM patients to ICUs and improve 
their prognosis. In summary, the existing evidence sug-
gests that HM patients with single organ failure should be 
promptly admitted to the ICU and that a close collabora-
tion between hematologists and ICU specialists is benefi-
cial for patient care (Table 1). 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 10 of 12Cheng et al. SpringerPlus  (2016) 5:2038 
Conclusions
Many studies have investigated the prognostic factors for 
HM patients admitted to the ICU. Some factors identi-
fied in the earlier studies, such as age, underlying diagno-
sis of malignancy, and disease status, were proven to be 
irrelevant in more recent studies. The role of other clini-
cal factors, such as infection and neutropenia, remain 
controversial. Although the incorporation of compre-
hensive scoring systems for assessing overall health and 
organ failure status have helped clinicians to estimate 
prognosis, none is specific enough for predicting mortal-
ity in critically ill patients with HM.
The overall ICU mortality rate for HM patients ranges 
between 26 and 84.1%, and differs by study population 
and region. The mortality rate is comparably higher in 
Asian countries (Yeo et  al. 2012). Broader ICU admis-
sion policies are recommended to ensure earlier treat-
ment and for improving mortality. The admission of 
HM patients to the ICU raises ethical concerns for both 
the hematological and intensive care teams. The deci-
sion of transfer to the ICU has major consequences on 
end of life care for both the patients and their relatives. 
It affects the distribution of medical resources, human 
resources, and the organizational and economic aspects 
for the ICU and global health policy. A guiding princi-
ple for ICU admission is that it should be reserved for 
patients with reversible medical conditions and a rea-
sonable chance of substantial recovery. Thus, the basis 
of intensive care medicine is optimizing the patient’s 
physiology by delivering supportive therapy, while 
attempting to treat the underlying disease. With more 
scientific patient selection and unbiased judgment, the 
prognosis of HM patients admitted to the ICU may 
improve.
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